August 26, (THEWILL) – The Nigeria Centre for Disease Control and Prevention (NCDC) has said the new Omicron variant of the SARS-CoV-2 virus named BA.2.86 is not in Nigeria and there has not been an increase in cases of COVID-19 in the country.
NCDC Director General, Dr. Ifedayo Adetifa, made this known in a statement on Saturday.
Adetifa said while cases of the variants had been reported in 51 countries, risk assessment by the World Health Organisation (WHO) indicated that the new variant poses a low risk at the global level.
“In addition, EG.5 has not been associated with any change in symptoms/clinical manifestation and has not produced an increase in severity of illness and/or hospitalisations or difference in death rates in reporting countries,” he said.
Adetifa urged Nigerians including media practitioners to act responsibly and share only verified information.
The statement reads in part: “So far, only one case of EG.5 has been seen in Africa, it has not been identified in Nigeria.
“The recently discovered/reported BA.2.86 is a descendent lineage of BA.2 (a sublineage of Omicron, also found in Nigeria in 2022). As of August 23, 2023, the BA.2.86 variant had been reported in a handful of countries – the United Kingdom, Israel, Denmark, South Africa, and the United States.
“It has been classified by the WHO as a “variant under monitoring (VUM)” because it has multiple genetic differences that make it substantially different from its ancestor, BA.2 and from other currently circulating XBB-derived SARS-CoV-2 variants.
“Since there are few cases identified so far, there is not enough information to make conclusive assessments of virulence, transmission, and severity. However, we do not expect it to be much different from other omicron descendants currently circulating. Although the ancestor, BA.2 has been previously found in Nigeria, no BA.2.86 variant has been identified in Nigeria.
“The NCDC’s COVID-19 Technical Working Group (COVID-19 TWG) is closely monitoring COVID-19 epidemiology – local, regional, continental, and global – including emerging variants.
“Our influenza sentinel surveillance sites continue to provide information on COVID-19 prevalence in patients with influenza-like illness and severe acute respiratory illness.
“We have not observed any increase in the trend of COVID-19 in this patient group. We continue to carry out genomics surveillance even with the low testing levels and encourage testing locations in states to ensure their positive samples are sent to the NCDC for sequencing.
“Unrelated to the news of these emerging variants, the NCDC and partners are working on implementing an enhanced COVID-19 testing exercise in four states to obtain complementary and more detailed information about circulating variants in the country. In addition, COVID-19 rapid diagnostic kits are being distributed for the purpose of improving bi-directional COVID-19 testing.
“There is no need to cause unnecessary anxiety and panic. As we have consistently advised, COVID-19 is here to stay and is now mainly a problem for those at high risk – the elderly, those with underlying chronic illnesses, especially hypertension and diabetes, those on cancer treatment, organ transplant recipients and those whose immune systems are suppressed for one reason or the other.”
The statement added that actions “individuals and families need to take in preventing the infection include testing for any febrile illness and respiratory symptoms regardless of how mild to be sure it’s not COVID, vaccination against COVID-19, good hand hygiene by washing hands regularly with soap under running water and wearing of masks by individuals with flu-like symptoms like coughing and sneezing.”
